Description: In this webcast, presenters will outline the key content in ERM ASOPs 46, 47 and 55 and explore the impact each ASOP has on practitioners working in these fields. We will also describe the revision work currently under way in the ERM Committee of the Actuarial Standards Board.

Description: 2021 ImpACT Conference - Session 12B: Revised ASOP 11: Are Life, Annuity, and Health Actuaries Ready? 10.29.21 Recording

Description: In today’s market of post-pandemic consolidation and org chart streamlining, we’ve observed significant changes to actuarial career development and advancement opportunities. But, those changes aren’t occurring in equal measures across the arc of the actuarial career. Our focus is on the impact felt by experienced reinsurance actuaries.

Description: Status update of the activities through the year 2021, and upcoming activities, with the Reinsurance Section Council

Description: The Life Meeting, is the result of combining the Life & Annuity Symposium (LAS) and the Valuation Actuarial Symposium (ValAct). The Life Meeting will offer sessions specific to pricing and valuation as well as sessions on emerging issues relevant to both groups. These common themes include InsurTech, diversity, accounting change and the current economic environment.

Description: In this interview, Caroline Grégoire, formerly from Hannover Re, and now international mentor, coach, trainer and speaker, shares her views on how mentoring can support you on your career path and how it also benefits the reinsurance industry as a whole.

Description: This year’s Life Meeting was unable to take place in person as planned in New York City. We are looking forward to the Life Meeting returning to New York City in 2024!

Description: This article reports on the latest annual survey about the relationship between reinsurers and their cedant clients. Some improvement was seen in 2011 from both actuaries and underwriters.

Description: Life insurance has no shortage of issues and innovations impacting the day-to-day life of products, a product actuary and the life insurance process. Listen to a group of experts discuss the key topics faced when issuing and managing life products, including innovations, regulations, growth, opportunity and cautions pertaining to Term, whole life, and UL products. By attending the session, you will: Be able to identify trends in life products and processes, avoid pitfalls of product development through increased awareness of innovations and issues, and identify key developments that could impact life products.

Description: Almost half of recent FDA approvals have been for orphan drugs. This trend is expected to continue in 2023. Orphan drugs are priced more than 30 times higher than non-orphan drugs, therefore their cost burden in aggregate has the potential to overwhelm the budgets of payers, especially that of smaller health plans. Hear how the cost impact analysis for smaller health plans require different considerations than for a larger health plan when modeling the impact of rare diseases.